2021
Uptake and effectiveness of checkpoint inhibitor therapy among trial-ineligible patients with advanced solid malignancies.
Parikh R, Min E, Wileyto E, Riaz F, Gross C, Cohen R, Hubbard R, Long Q, Mamtani R. Uptake and effectiveness of checkpoint inhibitor therapy among trial-ineligible patients with advanced solid malignancies. Journal Of Clinical Oncology 2021, 39: e18595-e18595. DOI: 10.1200/jco.2021.39.15_suppl.e18595.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsNon-ICI therapyAdvanced solid malignanciesICI monotherapyPerformance statusEarly mortalitySolid malignanciesFlatiron Health electronic health record-derived databaseElectronic health record-derived databaseFirst-line immune checkpoint inhibitorsNon-small cell lungInverse probabilityICI combination therapyTrial-ineligible patientsCheckpoint inhibitor therapyECOG performance statusPoor performance statusRetrospective cohort studyPhase III trialsCommunity oncology practicesPivotal clinical trialsMean survival timeTime-varying hazard ratiosPart of standardCheckpoint inhibitors
2019
Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States
Huntington S, Soulos P, Barr P, Jacobs R, Lansigan F, Odejide O, Schwartzberg L, Davidoff A, Gross C. Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States. Blood 2019, 134: 797. DOI: 10.1182/blood-2019-122054.Peer-Reviewed Original ResearchFirst-line settingChronic lymphocytic leukemiaFlatiron Health databaseECOG performance statusFirst-line treatmentEarly discontinuationMultivariable logistic regressionPerformance statusIbrutinib discontinuationSpeakers bureauClinical trialsCLL diagnosisCLL therapyLymphocytic leukemiaHealth databasesLogistic regressionBruton tyrosine kinase inhibitorsFirst-line ibrutinibUse of ibrutinibWorse performance statusPoor performance statusRetrospective cohort studyCommunity oncology settingClinical decision support toolCommunity oncology practicesChromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents.
Giri S, Huntington S, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A, Neparidze N. Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents. Journal Of Clinical Oncology 2019, 37: 8044-8044. DOI: 10.1200/jco.2019.37.15_suppl.8044.Peer-Reviewed Original ResearchOverall survivalMultiple myelomaPerformance statusMultivariable Cox survival analysisMedian overall survivalPoor performance statusLines of therapyKaplan-Meier methodCox regression analysisDays of diagnosisWorse overall survivalCox survival analysisLog-rank testReal-world treatmentCommon genetic mutationsHigh-risk mutationsSitu hybridization testingElectronic health recordsISS stageReal-world practiceMedian ageMeier methodOS independentPrimary outcomeSpecific regimensTrends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma (aUC) at the end of life: Insights from real-world practice.
Parikh R, Galsky M, Gyawali B, Riaz F, Kaufmann T, Cohen A, Adamson B, Gross C, Meropol N, Mamtani R. Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma (aUC) at the end of life: Insights from real-world practice. Journal Of Clinical Oncology 2019, 37: 395-395. DOI: 10.1200/jco.2019.37.7_suppl.395.Peer-Reviewed Original ResearchAdvanced urothelial cell carcinomaPoor performance statusEnd of lifeSystemic therapyDay of deathQuarterly proportionPoor PSStudy periodFlatiron Health databaseSystemic therapy initiationCheckpoint inhibitor therapyFavorable toxicity profileUrothelial cell carcinomaDays of lifeSecular trend analysisChemotherapy initiationChemotherapy useCPI useReal-world practiceTherapy initiationInhibitor therapyPerformance statusPS 0Cell carcinomaNational guidelines